The Diagnostic Efficacy of Version 2018 LI-RADS for Hepatocellular Carcinoma on Enhanced Magnetic Resonance Imaging
Objectives: To evaluate the diagnostic performance of the 2018 version of liver reporting and date system (LI-RADS v2018) for hepatocellular carcinoma (HCC) on contrast-enhanced magnetic resonance imaging (MRI) in high-risk patients. Methods: The data from 69 patients with HCC confirmed by pathology...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Editorial Office of Computerized Tomography Theory and Application
2023-01-01
|
| Series: | CT Lilun yu yingyong yanjiu |
| Subjects: | |
| Online Access: | https://www.cttacn.org.cn/cn/article/doi/10.15953/j.ctta.2023.073 |
| _version_ | 1797359588747509760 |
|---|---|
| author | Sulan JIA Jingbo DU Xiaohua SU |
| author_facet | Sulan JIA Jingbo DU Xiaohua SU |
| author_sort | Sulan JIA |
| collection | DOAJ |
| description | Objectives: To evaluate the diagnostic performance of the 2018 version of liver reporting and date system (LI-RADS v2018) for hepatocellular carcinoma (HCC) on contrast-enhanced magnetic resonance imaging (MRI) in high-risk patients. Methods: The data from 69 patients with HCC confirmed by pathology from 2017 and 2022 were retrospectively analyzed. The MRI features of the HCC lesions were analyzed and categorized according to LI-RADS v2018. The efficacy of LI-RADS v2018 in the diagnosis of HCC was calculated based on pathology. The intraclass correlation coefficient (ICC) test was used for consistency analysis. Results: The ICC value of the LI-RADS categories was 0.782 (95%CI: 0.713 to 0.841) across three readers based on the Liver Imaging Reporting and Data System (LI-RADS) criteria. When using LR-5 as the criterion to predict HCCs, the sensitivity, specificity and accuracy for each reader were 83.9%, 70.4%, and 79.8%; 80.6%, 74.1%, and 78.7%; and 80.6%, 77.8%, and 79.8%, respectively. When using LR-4/5 as the criterion to predict HCCs, these measures for each reader were 93.5%, 63.0%, and 84.3%; 90.3%, 66.7%, and 83.1%; and 91.9%, 66.7%, and 84.3%, respectively. Conclusion: Based on LI-RADS v2018, the enhanced MRI demonstrated high diagnostic efficacy for HCC in high-risk patients. |
| first_indexed | 2024-03-08T15:25:55Z |
| format | Article |
| id | doaj.art-d19d68a1e27b4c479edf083805a42a4c |
| institution | Directory Open Access Journal |
| issn | 1004-4140 |
| language | English |
| last_indexed | 2024-03-08T15:25:55Z |
| publishDate | 2023-01-01 |
| publisher | Editorial Office of Computerized Tomography Theory and Application |
| record_format | Article |
| series | CT Lilun yu yingyong yanjiu |
| spelling | doaj.art-d19d68a1e27b4c479edf083805a42a4c2024-01-10T09:27:14ZengEditorial Office of Computerized Tomography Theory and ApplicationCT Lilun yu yingyong yanjiu1004-41402023-01-01331354110.15953/j.ctta.2023.0732023.073The Diagnostic Efficacy of Version 2018 LI-RADS for Hepatocellular Carcinoma on Enhanced Magnetic Resonance ImagingSulan JIA0Jingbo DU1Xiaohua SU2Department of Radiology, Beijing Daxing District Hospital, Beijing 102600, ChinaDepartment of Radiology, Beijing Daxing District Hospital, Beijing 102600, ChinaDepartment of Radiology, Beijing Daxing District Hospital, Beijing 102600, ChinaObjectives: To evaluate the diagnostic performance of the 2018 version of liver reporting and date system (LI-RADS v2018) for hepatocellular carcinoma (HCC) on contrast-enhanced magnetic resonance imaging (MRI) in high-risk patients. Methods: The data from 69 patients with HCC confirmed by pathology from 2017 and 2022 were retrospectively analyzed. The MRI features of the HCC lesions were analyzed and categorized according to LI-RADS v2018. The efficacy of LI-RADS v2018 in the diagnosis of HCC was calculated based on pathology. The intraclass correlation coefficient (ICC) test was used for consistency analysis. Results: The ICC value of the LI-RADS categories was 0.782 (95%CI: 0.713 to 0.841) across three readers based on the Liver Imaging Reporting and Data System (LI-RADS) criteria. When using LR-5 as the criterion to predict HCCs, the sensitivity, specificity and accuracy for each reader were 83.9%, 70.4%, and 79.8%; 80.6%, 74.1%, and 78.7%; and 80.6%, 77.8%, and 79.8%, respectively. When using LR-4/5 as the criterion to predict HCCs, these measures for each reader were 93.5%, 63.0%, and 84.3%; 90.3%, 66.7%, and 83.1%; and 91.9%, 66.7%, and 84.3%, respectively. Conclusion: Based on LI-RADS v2018, the enhanced MRI demonstrated high diagnostic efficacy for HCC in high-risk patients.https://www.cttacn.org.cn/cn/article/doi/10.15953/j.ctta.2023.073magnetic resonance imaginghepatocellular carcinomaliver imaging reporting and data system version 2018 |
| spellingShingle | Sulan JIA Jingbo DU Xiaohua SU The Diagnostic Efficacy of Version 2018 LI-RADS for Hepatocellular Carcinoma on Enhanced Magnetic Resonance Imaging CT Lilun yu yingyong yanjiu magnetic resonance imaging hepatocellular carcinoma liver imaging reporting and data system version 2018 |
| title | The Diagnostic Efficacy of Version 2018 LI-RADS for Hepatocellular Carcinoma on Enhanced Magnetic Resonance Imaging |
| title_full | The Diagnostic Efficacy of Version 2018 LI-RADS for Hepatocellular Carcinoma on Enhanced Magnetic Resonance Imaging |
| title_fullStr | The Diagnostic Efficacy of Version 2018 LI-RADS for Hepatocellular Carcinoma on Enhanced Magnetic Resonance Imaging |
| title_full_unstemmed | The Diagnostic Efficacy of Version 2018 LI-RADS for Hepatocellular Carcinoma on Enhanced Magnetic Resonance Imaging |
| title_short | The Diagnostic Efficacy of Version 2018 LI-RADS for Hepatocellular Carcinoma on Enhanced Magnetic Resonance Imaging |
| title_sort | diagnostic efficacy of version 2018 li rads for hepatocellular carcinoma on enhanced magnetic resonance imaging |
| topic | magnetic resonance imaging hepatocellular carcinoma liver imaging reporting and data system version 2018 |
| url | https://www.cttacn.org.cn/cn/article/doi/10.15953/j.ctta.2023.073 |
| work_keys_str_mv | AT sulanjia thediagnosticefficacyofversion2018liradsforhepatocellularcarcinomaonenhancedmagneticresonanceimaging AT jingbodu thediagnosticefficacyofversion2018liradsforhepatocellularcarcinomaonenhancedmagneticresonanceimaging AT xiaohuasu thediagnosticefficacyofversion2018liradsforhepatocellularcarcinomaonenhancedmagneticresonanceimaging AT sulanjia diagnosticefficacyofversion2018liradsforhepatocellularcarcinomaonenhancedmagneticresonanceimaging AT jingbodu diagnosticefficacyofversion2018liradsforhepatocellularcarcinomaonenhancedmagneticresonanceimaging AT xiaohuasu diagnosticefficacyofversion2018liradsforhepatocellularcarcinomaonenhancedmagneticresonanceimaging |